Avoiding restenosis: Is there a role for glucocorticoids in the drug-eluting stent era?

Therapeutic Advances in Cardiovascular Disease

Volumn 2, Issue 3, 2008, Pages 137-146

  Jimenez Valero, Santiago ^a   Moreno, Raul ^a   Sanchez Recalde, Angel ^a   Galeote, Guillermo ^a   Calvo, Luis ^a   Viana, Ana ^a   Lopez, Esteban ^a   López Sendón, Jose ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Drug Eluting Stent; Glucocorticoids; Restenosis; Stent; Steroids

Indexed keywords

ANTICOAGULANT AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DEXAMET; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETANSERIN; METHYLPREDNISOLONE; PACLITAXEL; PLACEBO; PREDNISONE; PROBUCOL; PROBUCOL SUCCINATE; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TRANILAST; TRAPIDIL; VITAMIN;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY STENT; DISEASE CONTROL; DRUG ADMINISTRATION ROUTE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; INFLAMMATION; INTRACORONARY DRUG ADMINISTRATION; LOW DRUG DOSE; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STOMACH PAIN; UNSPECIFIED SIDE EFFECT; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS AS TOPIC; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION;

EID: 59649091558     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944708090573     Document Type: Review

References (65)

1. Barnes, P.J. (2005) Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 25: 451-468.
2. Bavry, A.A., Chiu, J.H., Jefferson, B.K., Karha, J., Bhatt, D.L. and Ellis, S.G. (2007) Development of coronary aneurysm after drug-eluting stent implantation. Ann Intern Med 146: 230-232.
3. Buffon, A., Liuzzo, G., Biasucci, L.M., Pasqualetti, P., Ramazzotti, V., Rebuzzi, A.G. et al. (1999) Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 34: 1512-1521.
4. Dibra, A., Mehili, J., Braun, S., Hadamitzky, M., Baum, H., Dirschinger, J. et al. (2005) Inflammatory response after intervention assesed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 150: 344-350.
5. Douglas, J.S. (2007) Pharmacologic approaches to restenosis prevention. Am J Cardiol 100: 10K-16K.
6. Farb, A., Weber, D.K., Kolodgie, F.D., Burke, A.P. and Virmani, R. (2002) Morphological predictors of restenosis after coronary stenting in humans. Circulation 105: 2974-2980.
7. Ferrero, V., Ribichini, F., Pesarini, G., Brunelleschi, S. and Vassanelli, C. (2007 a) Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential. Drugs 67: 1243-1255.
8. Ferrero, V., Ribichini, F., Rognoni, A., Marino, P., Brunelleschi, S. and Vassanelli, C. (2007 b) Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study). Am J Cardiol 99: 1082-1086.
9. Finn, A.V., Nakazawa, G., Joner, M., Kolodgie, F.D., Mont, E.K., Gold, H.K. et al. (2007) Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27: 1500-1510.
10. Fukuda, D., Shimada, K., Tanaka, A., Kawarabayashi, T., Yoshiyama, M. and Yoshikawa, J. (2004) Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol 43: 18-23.
11. Fuster, V., Moreno, P.R., Fayad, Z.A., Corti, R. and Badimon, J.J. (2005) Atherothrombosis and high risk plaque. Part I: Evolving concepts. J Am Coll Cardiol 46: 937-954.
12. Garas, S.M., Huber, P. and Scout, N.A. (2001) Overview of therapies for prevention of restenosis alter coronary interventions. Pharmacol Ther 92: 165-178.
13. Gaspardone, A. and Versaci, F. (2005) Coronary stenting and inflammation. Am J Cardiol 96: 65L-70L.
14. Gaspardone, A., Versaci, F., Tomai, F., Citone, C., Proietti, I., Gioffrè, G. et al. (2006) C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol 97: 1311-1316.
15. Grines, C.L., Bonow, R.O., Casey, D.E. Jr., Gardner, T.J., Lockhart, P.B., Moliterno, D.J. et al. (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49: 734-739.
16. Han, S.H., Ahn, T.H., Kang, W.C., Oh, K.J., Chung, W.J., Shin, M.S. et al. (2006) The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: randomized controlled prospective study. Am Heart J 152: 887.e1-887.e7.
17. Hara, H., Nakamura, M., Palmaz, J.C. and Schwartz, R.S. (2006) Role of stent design and coatings on restenosis and thrombosis. Adv Drug Deliv Rev 58: 377-386.
18. Hoffmann, R., Langenberg, R., Radke, P., Franke, A., Blindt, R., Ortlepp, J. et al. (2004) Evaluation of a high-dose dexamethasone-eluting stent. Am J Cardiol 15;94: 193-195.
19. Hojo, Y., Ikeda, U., Katsuki, T., Mizuno, O., Fukazawa, H., Kurosaki, K. et al. (2000) Interleukin 6 expression in coronary circulation after coronary angioplasty as risk factor for restenosis. Heart 84: 83-87.
20. Holmes Jr, D.R., Kereiakes, D.J., Laskey, W.K., Colombo, A., Ellis, S.G., Henry, T.D. et al. (2007) Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol 50: 109-118.
21. Huang, Y., Liu, X., Wang, L., Verbeken, E., Li, S. and de Scheerder, I. (2003) Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model. Int J Cardiovasc Intervent 5: 166-171.
22. Jaffe, R. and Strauss, B.H. (2007) Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol 50: 119-127.
23. Jimenez-Valero, S., Santos, B., Pajin, F., Canton, T., Lazaro, E., Moreu, J. et al. (2007) Clinical outcomes of dexamethasone-eluting stent implantation in ST-elevation acute myocardial infarction. Catheter Cardiovasc Interv 70: 492-497.
24. Kastrati, A., Mehilli, J., Dirschinger, J., Dotzer, F., Schünlen, H., Neumann, F.J. et al. (2001) Intracoronary stenting and angiographic results. Strut thickness effect on restenosis outcome (ISAR-STEREO) Trial. Circulation 103: 2816-2821.
25. König, A., Leibig, M., Rieber, J., Schiele, T.M., Theisen, K., Siebert, U. et al. (2007) Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. Am Heart J 153: 979.e1-979.e8.
26. Kuchulakanti, P. and Waksman, R. (2004) Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis. Drugs 64: 2379-2388.
27. Lee, C.W., Chae, J.K., Lim, H.Y., Hong, M.K., Kim, J.J. and Park, S.W. (1999) Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J 138: 60-63.
28. Lew, R., Ajani, A. and Waksman, R. (2003) Review of intracoronary radiation for in-stent restenosis. J Invasive Cardiol Suppl A: 2A-8A.
29. Liu, X., Huang, Y., Hanet, C., Vandormael, M., Legrand, V., Dens, J. et al. (2003) Study of antirestenosis with the BiodivYsio Dexamethasone-eluting stent (STRIDE). Cath Cardiovasc Intervent 60: 172-178.
30. Liuzzo, G., Santamaria, M., Biasucci, L.M., Narducci, M., Colafrancesco, V., Porto, A. et al. (2007) Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein. J Am Coll Cardiol 49: 185-194.
31. Lowe, H.C., Oesterle, S.N. and Khachigian, L.M. (2002) Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 39: 183-193.
32. Lucas, R.A., Korol, R. and Pepine, C.J. (2006) Inflammation in atherosclerosis. Some thoughts about acute coronary syndromes. Circulation 113: e728-e732.
33. McDonald, R.G., Panush, R.S. and Pepine, C.J. (1987) Rationale for use of glucocorticoids in modification of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 60: 56B-60B.
34. Menown, I., Lowe, R. and Penn, I. (2005) Passive stent coatings in the drug-eluting era. J Invasive Cardiol 17: 222-228.
35. Moreno, R. (2005) Drug-eluting stents and other anti-restenosis devices. Rev Esp Cardiol 58: 842-862.
36. Moreno, R., Fernandez, C., Sanchez-Recalde, A., Galeote, G., Calvo, L., Alfonso, F. et al. (2007) Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J 28: 1583-1591.
37. Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., Caputo, R.P. et al. (2003) Sirolimus-eluting stent versus standard stent in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315-1323.
38. Mueller, C., Buettner, H.J., Hodgson, J.D., Marsch, S., Perruchoud, A.P., Roskamm, H. et al. (2006) Inflammation and long-term mortality after non ST-elevation acute coronary syndromes treated with a very early invasive strategy in 1042 consecutive patients. Circulation 105: 1412-1415.
39. Nebeker, J.R., Virmani, R., Bennett, C.L., Hoffman, J.M., Samore, M.H., Alvarez, J. et al. (2006) Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47: 175-181.
40. Nissen, S.E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
41. Ong, A.T., Daemen, J., van Hoult, B.A., Lemos, P.A., Bosch, J.L., van Domburg, R.T. et al. (2006) Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up. Results from the RESEARCH registry. Eur Heart J 27: 2996-3003.
42. Patti, G., Chello, M., Pasceri, V., Colonna, D., Carminati, P., Covino, E. et al. (2005 a) Dexamethasone-eluting stents and plasma concentrations of adhesion molecules in patients with unstable coronary syndromes: results of the historically controlled SESAME study. Clin Ther 27: 1411-1419.
43. Patti, G., Pasceri, V., Carminati, P., D'Ambrosio, A., Carcagnì, A. and Di Sciascio, G. (2005 b) Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 95: 502-505.
44. Pepine, C.J., Hirshfeld, J.W., Macdonald, R.G., Henderson, M.A., Bass, T.A., Goldberg, S. et al. (1990) A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation 81: 1753-1761.
45. Rajagopal, V. and Rockson, S.G. (2003) coronary restenosis: a review of mechanisms and management. Am J Med 115: 547-553.
46. Rhen, T. and Cidlowski, J.A. (2005) Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 353: 1711-1723.
47. Ribichini, F., Tomai, F., Ferrero, V. Versaci, F., Bocuzzi, G., Proietti, I. et al. (2005) Immunosuppressive oral prednisone alter percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS 2/MVD study. Eurointerv 1: 173-180.
48. Ribichini, F., Joner, M., Ferrero, V., Finn, A.V., Crimins, J., Nakazawa, G. et al. (2007 a) Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis. J Am Coll Cardiol 50: 176-185.
49. Ribichini, F., Ferrero, V., Rognoni, A., Marino, P., Brunelleschi, S. and Vassanelli, C. (2007 b) Percutaneous treatment of coronary bifurcations: lesion preparation before provisional bare metal stenting and subsequent immunosuppression with oral prednisone. The IMPRESS-Y study. J Interv Cardiol 20: 114-121.
50. Ribichini, F., Ferrero, V., Feola, M., Rognoni, A., Brunelleschi, S., Vacca., G. et al. (2007 c) Neutropenia in patients treated with thienopiridines and high-dose oral prednisone after percutaneous coronary interventions. J Interv Cardiol 20: 209-213.
51. Ribichini, F., Tomai, F., Paloscia, L., Di Sciascio, G., Carosio, G., Romano, M. et al. (2007 d) Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. Heart 93: 598-600.
52. Rittersma, S., de Winter, R.J., Koch, K., Bax, M., Schotborgh, C.E., Mulder, K.J. et al. (2004) Impact of strut thickness on late luminal loss after coronary artery stent placement. Am J Cardiol 93: 477-480.
53. Rodriguez, A.E., Granada, J.F., Rodriguez-Alemparte, M.„ Vigo, C.F., Delgado, J., Fernandez-Pereira, C. et al. (2006) Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 47: 1522-1529.
54. Rosmarakis, E.S. and Falagas, M.E. (2007) Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J 154: 144-150.
55. Ross, R. (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126.
56. Saleh, N. and Tornvall, P. (2007) Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis 195: 374-378.
57. Stone, G.W., Ellis, S.G., Cox, D.A., Hermiller, J., O'Shaughnessy, C., Mann, J.T. et al. (2004) A polymer based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350: 221-231.
58. Toutouzas, K., Colombo, A. and Stefanadis, C. (2004) Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 25: 1679-1687.
59. Versaci, F., Gaspardone, A., Tomai, F., Ribichini, F., Russo, P., Proietti, I. et al. (2002) Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 40: 1935-1942.
60. Waksman, R., Ajani, A.E., Pichard, A.D., Torguson, R., Pinnow, E., Canos, D. et al. (2004) Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 44: 1386-1392.
61. Walker, B.R. (2007) Glucocorticoids and cardiovascular disease. Eur J Endocrinol 157: 545-559.
62. Wang, L., Salu, K., Verbeken, E., Bosmans, J., van de Werf, F. and de Scheerder, I. (2005) Stent-mediated methylprednisolone delivery reduces macrophage contents and in-stent neointimal formation. Coron Artery Dis 16: 237-243.
63. Weintraub, W.S. (2007) The pathophysiology and burden of restenosis. Am J Cardiol 100[suppl]: 3K-9K.
64. Welt, F.G. and Rogers, C. (2002) Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22: 1769-1776.
65. Wijns, W. (2005) Blowing against the wind? Eurointervention 1: 127-128.